ClinicalTrials.gg
RecruitingNCT07145086Updated Aug 28, 2025

Translaryngeal Vibration for Hyperfunctional Voice Disorders

A Phase 3 interventional study of Voice therapy with vibration in Dysphonia and Muscle Tension Dysphonia, sponsored by Texas Christian University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-28.

Sponsored by Texas Christian University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Sep 2024, registered Aug 2025).
  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 71 studies in Dysphonia with a site in United States — 20 open to participants now, 21 under way, 1 of them phase 3. Dysphonia · United States.

Planned enrollment
29th of 53
30 · median 32
Started
2024
the only one that year
Phase 3
2 of 71
1 open now
Primary completion
2027-04
later than 5 of 20 live
Registered
69th of 71
by date

Among the 71 studies in Dysphonia with a site in United States, this one is the 29th largest by planned enrollment of the 53 interventional ones that give a count, is the only one that started in 2024, is one of 2 in phase 3, reaches primary completion later than 5 of the 20 other live ones, and was the 69th registered.

Dysphonia

132 studies on the registry are indexed under Dysphonia; 38 are open to participants now.

Browse Dysphonia studies →

Open to participants now

20 of the 71 studies in Dysphonia with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Dysphonia studies recruiting now, 8 (32%) set no upper age limit and 9 (36%) stop at 75 or younger; 7 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Dysphonia with a site in United States, or all of them as a file.
02

Study summary

Contemporary treatments for hyperfunctional voice disorders such as muscle tension dysphonia (MTD) are effective but typically do not restore voice handicap or voice function to normal thresholds. Recent reports of vibration as a voice therapy modality have been published, but many questions remain about the efficacy of this tool. The current project addresses these problems through a blinded and randomized controlled trial to investigate the efficacy of local translaryngeal vibration for MTD and the dose-response relationship of this modality when compared to treatment without vibration.

Read the detailed description

High-quality research designs have demonstrated that voice therapy has a positive impact on hyperfunctional voice disorders associated with muscle tension dysphonia (MTD). Among the options of behavioral voice therapy for MTD, one of the most effective evidence-based approaches is flow phonation (a.k.a., stretch-and-flow voice therapy). However, the phenomenon of post-treatment outcome measures remaining substantially outside the range of normal is a ubiquitous finding in studies investigating this and other voice therapy approaches. From both a cost burden and quality of life perspective, this phenomenon supports a need to develop and refine voice therapy treatment approaches to promote better outcomes. Vibration is a physical modality that has a historical use in the rehabilitation professions, but only recently has it been scientifically studied as a modality for voice therapy when used by speech-language pathologists. When applied locally on the perilaryngeal surface as a local translaryngeal vibration therapy (LTLV), early research has demonstrated beneficial effects on voice physiology and clinical outcomes. Further high-quality clinical research studies are needed to evaluate the efficacy of LTLV as a modality for voice disorders and to better understand the effects of vibration and effective vibration dose on voice rehabilitation outcomes. The research proposed in this R15 has the potential to transform clinical practice of treatment for MTD, the most common voice disorder among treatment-seeking populations. That potential is vested in the pursuit of three specific aims: (1) determine the clinical efficacy of LTLV as a concurrent treatment using flow phonation voice therapy in patients with MTD, and (2) determine the effect of treatment dose on clinical response associated with treatment outcomes. In addition to the potential impact of this R15, the innovative of approach of using LTLV as a concurrent modality with flow phonation combined with investigation of the most effective frequency parameter for clinical application represents a pioneering approach to advance the field of clinical voice practice in speech-language pathology.

03

Conditions studied

  • Dysphonia
  • Muscle Tension Dysphonia

Browse trials for

Keywords

  • Dysphonia
  • Muscle Tension Dysphonia
  • Voice Therapy
  • Vibration
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • a) diagnosis by an otolaryngologist of hyperfunctional dysphonia (MTD) without benign mid-membranous lesion (i.e., primary MTD or non-phonotraumatic hyperfunction) with and a recommendation for voice therapy, ((b) confirmation of dysphonia by a comprehensive voice evaluation conducted by a speech-language pathologist with experience in the evaluation and treatment of voice disordered populations, (c) to prevent floor effects of our primary outcome variable, participants will be required to exhibit a pre-treatment VHI score of >20, as this is the upper range for normal cutoff values in studies which have demonstrated high sensitivity and specificity for this tool (Behlau et al., 2016), (d) 18 years of age or older, (e) no history of local vibration therapy as part of a rehabilitation treatment program.

Exclusion criteria

Exclusion Criteria:

  • Unable to receive vibration to neck area
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Five Week Therapy

    Participants receive five weeks of voice therapy with vibration

    Behavioral: Voice therapy with vibration

  • Active comparator
    Eight Week Therapy

    Participants receive eight weeks of voice therapy with vibration

    Behavioral: Voice therapy with vibration

  • Placebo comparator
    Voice Therapy with Placebo

    Participants receive eight weeks of voice therapy with vibration placebo

    Behavioral: Voice therapy with vibration

Interventions

  • BehavioralVoice therapy with vibration

    Voice therapy with a novel vibration device will be delivered for five or eight weeks depending on group allocation. All participants will receive flow phonation voice therapy.

06

What researchers measure

Primary outcomes

  1. Voice Handicap Index

    The Voice Handicap Index (VHI) is a self-assessment tool used to evaluate how a voice disorder impacts a person's daily life, encompassing functional, physical, and emotional aspects. It helps quantify the perceived handicap caused by a voice problem, aiding in diagnosis, treatment planning, and assessing treatment effectiveness. The VHI consists of 30 questions, divided into three subscales, with scores ranging from 0 to 120, where higher scores indicate a greater perceived handicap

    Time frame: From enrollment to the end of treatment at 5 or 8 weeks"

Secondary outcomes

  1. Consensus Auditory-Perceptual Evaluation of Voice

    Perceptual Voice Quality measurement

    Time frame: From enrollment to the end of treatment at 5 or 8 weeks"

07

Study locations

1 of 1 sites recruiting
  • Texas Christian University
    Fort Worth, Texas 76109, United States
    Recruiting
    • Christopher R Watts, Ph.D. · Contactc.watts@tcu.edu · 817-257-6878
    • Christopher R Watts, Ph.D. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2024 (actual). Primary completion is estimated for Apr 2027, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2025
First posted
Aug 28, 2025
StartActual
Sep 1, 2024
Primary completionEst.
Apr 30, 2027
CompletionEst.
Aug 31, 2027
Last update
Aug 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07145086
Lead sponsor
Texas Christian University
Responsible party
Sponsor
First posted
Aug 28, 2025
Start date
Sep 1, 2024
Primary completion
Apr 30, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Aug 28, 2025

Study contacts

Christopher R Watts, Ph.D.
Contact
c.watts@tcu.edu
817-266-7891

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion